Segers K, Backhovens H, Singh S K, De Voecht J, Ramael M, Van Broeckhoven C, Van Marck E
University of Antwerp (UIA), Department of Medicine, Belgium.
Virchows Arch. 1995;427(4):431-6. doi: 10.1007/BF00199393.
Previous immunohistochemical studies on malignant mesothelioma with antibodies recognizing both the wild and the mutant types of the p53 protein have shown immunoreactivity in 25-70% of cases. This study was designed to determine whether there is immunoreactivity for p53 and mdm2 protein in malignant mesothelioma and to correlate p53 expression with the detection of mutations in p53 at DNA level. In 10 of 15 cases there was immunoreactivity for p53. In 6 of these cases immunoreactivity for mdm2 was also detected. In one p53-immunonegative case, a mutation of the p53 gene resulting in a stop codon was found. These results suggest that mdm2 might be involved in the inhibition of p53 in malignant mesothelioma. Also, these data suggest the existence of other proteins than mdm2 that may associate with p53.
先前利用能识别野生型和突变型p53蛋白的抗体对恶性间皮瘤进行的免疫组化研究显示，25%至70%的病例存在免疫反应性。本研究旨在确定恶性间皮瘤中p53和mdm2蛋白是否存在免疫反应性，并将p53表达与DNA水平上p53突变的检测相关联。15例病例中有10例p53存在免疫反应性。其中6例还检测到mdm2的免疫反应性。在1例p53免疫阴性的病例中，发现了p53基因的一个导致终止密码子的突变。这些结果表明，mdm2可能参与恶性间皮瘤中p53的抑制作用。此外，这些数据表明，除mdm2外，可能还有其他蛋白质与p53相关联。
